Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

403 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reply to "Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma" by Mesbah Ardakani et al.
Boespflug A, Funck-Brentano E, Hélias-Rodzewicz Z, Maucort-Boulch D, Beauchet A, Bringuier PP, Dumontet C, Emile JF, Saiag P, Dalle S. Boespflug A, et al. Among authors: dumontet c. Pigment Cell Melanoma Res. 2017 Sep;30(5):498-500. doi: 10.1111/pcmr.12606. Epub 2017 Jul 23. Pigment Cell Melanoma Res. 2017. PMID: 28627072 No abstract available.
Monoclonal antibodies in clinical oncology.
Dalle S, Thieblemont C, Thomas L, Dumontet C. Dalle S, et al. Among authors: dumontet c. Anticancer Agents Med Chem. 2008 Jun;8(5):523-32. doi: 10.2174/187152008784533071. Anticancer Agents Med Chem. 2008. PMID: 18537534 Review.
In vivo model of follicular lymphoma resistant to rituximab.
Dalle S, Dupire S, Brunet-Manquat S, Reslan L, Plesa A, Dumontet C. Dalle S, et al. Among authors: dumontet c. Clin Cancer Res. 2009 Feb 1;15(3):851-7. doi: 10.1158/1078-0432.CCR-08-1685. Clin Cancer Res. 2009. PMID: 19188155
Primary cutaneous marginal zone lymphoma.
Dalle S, Thomas L, Balme B, Dumontet C, Thieblemont C. Dalle S, et al. Among authors: dumontet c. Crit Rev Oncol Hematol. 2010 Jun;74(3):156-62. doi: 10.1016/j.critrevonc.2009.09.003. Epub 2009 Oct 12. Crit Rev Oncol Hematol. 2010. PMID: 19819717 Review.
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
Maréchal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, André T, Dumontet C, Cass CE, Jordheim LP, Matera EL, Closset J, Salmon I, Devière J, Emile JF, Van Laethem JL. Maréchal R, et al. Among authors: dumontet c. Gastroenterology. 2012 Sep;143(3):664-674.e6. doi: 10.1053/j.gastro.2012.06.006. Epub 2012 Jun 13. Gastroenterology. 2012. PMID: 22705007
TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.
Mohamed AM, Balsat M, Koering C, Maucort-Boulch D, Boissel N, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, Tigaud I, Hayette S, Dumontet C, Cros E, Flandrin-Gresta P, Nibourel O, Preudhomme C, Thomas X, Nicolini FE, Solly F, Guyotat D, Campos L, Michallet M, Ceraulo A, Mortreux F, Wattel E. Mohamed AM, et al. Among authors: dumontet c. Leuk Res. 2017 May;56:21-28. doi: 10.1016/j.leukres.2017.01.012. Epub 2017 Jan 16. Leuk Res. 2017. PMID: 28167452
403 results